{"References": [{"title": "Pharmacogenetics of antiplatelet therapy: how far are we from clinical implementation?", "authors": "Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel PA", "journal": "Journal of the American College of Cardiology", "year": "2010", "volumes": "56", "first page": "934", "last page": "949", "DOI": "10.1016/j.jacc.2010.03.084"}, {"title": "CYP2C19 genotype and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel: a systematic review and meta-analysis", "authors": "Jiang XL, Samant S, Lesko LJ, Schmidt S", "journal": "Journal of the American Medical Association", "year": "2014", "volumes": "312", "first page": "1881", "last page": "1890", "DOI": "10.1001/jama.2014.14681"}, {"title": "Impact of CYP2C19 polymorphisms on antiplatelet effect and clinical outcomes in patients treated with clopidogrel: a systematic review and meta-analysis", "authors": "Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC", "journal": "Journal of the American Heart Association", "year": "2017", "volumes": "6", "first page": "e006947", "last page": "", "DOI": "10.1161/JAHA.117.006947"}, {"title": "Pharmacogenomics of clopidogrel: a comparison of CYP2C19 genotyping assays", "authors": "Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR", "journal": "Clinical Pharmacology & Therapeutics", "year": "2012", "volumes": "91", "first page": "540", "last page": "546", "DOI": "10.1038/clpt.2011.306"}, {"title": "CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel: a systematic review and meta-analysis", "authors": "Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP", "journal": "BMJ", "year": "2011", "volumes": "343", "first page": "d4588", "last page": "", "DOI": "10.1136/bmj.d4588"}, {"title": "Pharmacogenomics of antiplatelet therapy: steps toward personalized medicine", "authors": "Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L", "journal": "Journal of the American College of Cardiology", "year": "2013", "volumes": "62", "first page": "1693", "last page": "1701", "DOI": "10.1016/j.jacc.2013.07.017"}, {"title": "CYP2C19 genotype and clopidogrel efficacy", "authors": "Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E", "journal": "New England Journal of Medicine", "year": "2009", "volumes": "360", "first page": "354", "last page": "362", "DOI": "10.1056/NEJMoa0809171"}, {"title": "The role of CYP2C19 polymorphisms in determining clopidogrel efficacy", "authors": "Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Rousseau H, Blanchet B", "journal": "New England Journal of Medicine", "year": "2009", "volumes": "360", "first page": "363", "last page": "375", "DOI": "10.1056/NEJMoa0808227"}, {"title": "Pharmacogenetics of clopidogrel: CYP2C19 loss-of-function allele is associated with adverse clinical outcome in patients with acute coronary syndromes", "authors": "Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F", "journal": "European Heart Journal", "year": "2009", "volumes": "30", "first page": "1704", "last page": "1712", "DOI": "10.1093/eurheartj/ehp045"}, {"title": "CYP2C19 polymorphisms and the effect of clopidogrel on cardiovascular events", "authors": "Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Eikelboom JW", "journal": "New England Journal of Medicine", "year": "2010", "volumes": "363", "first page": "1704", "last page": "1714", "DOI": "10.1056/NEJMoa1008410"}]}